Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors

被引：0
|
作者：
Johanna C. Bendell
David S. Hong
Howard A. Burris
Aung Naing
Suzanne F. Jones
Gerald Falchook
Patricia Bricmont
Agnes Elekes
Edwin P. Rock
Razelle Kurzrock
机构：
[1] PLLC,Sarah Cannon Research Institute/Tennessee Oncology
[2] MD Anderson Cancer Center,Center for Personalized Cancer Therapy
[3] Otsuka Pharmaceutical Development and Commercialization,undefined
[4] Inc,undefined
[5] UC San Diego Moores Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词：
STAT3; OPB-31121; Dose escalation; Solid tumors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：125 / 130
页数：5
相关论文
共 50 条
  • [1] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell, Johanna C.
    Hong, David S.
    Burris, Howard A., III
    Naing, Aung
    Jones, Suzanne F.
    Falchook, Gerald
    Bricmont, Patricia
    Elekes, Agnes
    Rock, Edwin P.
    Kurzrock, Razelle
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) : 125 - 130
  • [2] A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced solid tumors
    Oh, D.
    Han, S.
    Kim, T. M.
    Lee, S.
    Kim, T.
    Heo, D. S.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Lee, Se-Hoon
    Han, Sae-Won
    Kim, Mi-Jung
    Kim, Tae-Min
    Kim, Tae-You
    Heo, Dae Seog
    Yuasa, Miyuki
    Yanagihara, Yasuo
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 607 - 615
  • [4] A phase I, open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in patients with advanced hepatocellular carcinoma (HCC).
    Ikeda, Masafumi
    Okusaka, Takuji
    Ishii, Hiroshi
    Yokosuka, Osamu
    Yoshida, Naoshi
    Yanaglhara, Yasuo
    Okita, Kiwamu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
    Myint, Han
    Shah, Satish
    Gutierrez, Martin
    Zsiros, Emese
    Nelson, Megan
    Zeidan, Stephanie
    Myrthil, Nadia
    Morawski, Aaron
    Barbu, Alina
    Shaik, Jahangheer
    Zhou, Chelsea
    Kanellopoulou, Chrysi
    Copeland, Ron
    Cusumano, Zachary
    Flies, Dallas
    Langermann, Solomon
    Lorusso, Patricia
    Odunsi, Kunle
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781
  • [6] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [7] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [8] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [9] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
12345